|
Volumn 368, Issue 6490, 2020, Pages 476-477
|
Against pandemic research exceptionalism
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BCG VACCINE;
HYDROXYCHLOROQUINE;
COVID-19 VACCINE;
VIRUS VACCINE;
DISEASE CONTROL;
EPIDEMIC;
RESEARCH WORK;
VACCINATION;
VACCINE;
VIRAL DISEASE;
VIRUS;
CAREGIVER;
CLINICAL DECISION MAKING;
CLINICIAN;
CORONAVIRUS DISEASE 2019;
DRUG DESIGN;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SCREENING;
EBOLA HEMORRHAGIC FEVER;
EPIDEMIC;
HEALTH CARE ACCESS;
HEALTH CARE POLICY;
HEALTH CARE QUALITY;
HEALTH CARE SYSTEM;
HUMAN;
LIFE EXPECTANCY;
MEDICAL ETHICS;
MEDICAL PRACTICE;
PANDEMIC;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
SOCIAL CONTROL;
SOCIAL RESPONSIBILITY;
SOCIAL WELFARE;
STAKEHOLDER ENGAGEMENT;
TREATMENT OUTCOME;
CLINICAL TRIAL (TOPIC);
CORONAVIRUS INFECTION;
ETHICS;
VIRUS PNEUMONIA;
CLINICAL TRIALS AS TOPIC;
CORONAVIRUS INFECTIONS;
HUMANS;
HYDROXYCHLOROQUINE;
PANDEMICS;
PNEUMONIA, VIRAL;
VIRAL VACCINES;
|
EID: 85084587493
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/SCIENCE.ABC1731 Document Type: Review |
Times cited : (250)
|
References (15)
|